Abstracts tagged "gout"

Abstract Number: 1633 • 2012 ACR/ARHP Annual Meeting
Ulodesine (BCX4208) Add-On Therapy to Allopurinol 300mg Lowers Hypoxanthine and Xanthine Plasma Levels in a Dose-Dependent Fashion: Results From a 12-Week Randomized Controlled Trial in Patients with Gout
Shanta Bantia¹, Leigh Harman², Cynthia Parker¹, Damon Papac³, Andreas Maetzel⁴, Brian Taubenheim⁴ and Alan S. Hollister⁴, ¹Discovery Biology, BioCryst Pharmaceuticals, Inc., Durham, NC, ²Bioanalytical Chemistry, BioCryst Pharmaceuticals, Inc., Durham, NC, ³Bioanalytical Sciences, Southern Research Institute, Birmingham, AL, ⁴Development, BioCryst Pharmaceuticals, Inc., Durham, NC
Background/Purpose: Ulodesine (BCX4208) is an oral, once-daily, purine nucleoside phosphorylase (PNP) inhibitor in clinical development as add-on therapy for the chronic management of hyperuricemia in…
Abstract Number: 139 • 2012 ACR/ARHP Annual Meeting
Lack of Effect of Supplemental Vitamin C On Serum Urate in Patients with Gout
Lisa K. Stamp¹, Christopher Frampton¹, John L. O'Donnell², Jill Drake³ and Peter T. Chapman⁴, ¹Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²Rheumatology Immunology & Allergy, Canterbury Health Laboratories, Christchurch, New Zealand, ³Rheumatology, Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand, ⁴Rheumatology, Immunology & Allergy, Christchurch Hospital, Christchurch, New Zealand
Background/Purpose: The key to effective long-term management of gout is sustained reduction of serum urate (SU) Methods: Patients with gout and a SU >0.36mmol/L…
Abstract Number: 2037 • 2012 ACR/ARHP Annual Meeting
Poor Quality of Gout Care Is Strongly Associated with Higher Gout-Related Health Care Utilization
Jasvinder A. Singh¹ and Joshua Richman², ¹Department of Medicine, University of Alabama, Tuscaloosa, AL, ²Biostatistics, UAB School of Medicine, Birmingham, AL
Background/Purpose: Proponents of improving quality of gout care have suggested various gout quality indicators, but no study to date has shown the link between…
Abstract Number: 813 • 2012 ACR/ARHP Annual Meeting
Rilonacept for Gout Flare Prophylaxis in Patients with Chronic Kidney Disease: Analysis of 3 Clinical Trials
Robert Terkeltaub¹, Robert R. Evans², Steven P. Weinstein³, Richard Wu⁴ and H. Ralph Schumacher⁵, ¹Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, ²Clinical Sciences, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ³Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ⁴BioStatistics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Department of Medicine, University of Pennsylvania and VA Medical Center, Philadelphia, PA
Background/Purpose: Gout flare (GF) prophylaxis in patients (pts) with chronic kidney disease (CKD; estimated glomerular filtration rate [eGFR]
Abstract Number: 140 • 2012 ACR/ARHP Annual Meeting
Patients That Continue to Flare Despite Apparent Optimal Urate Lowering Therapy
Dinesh Khanna¹, Puja Khanna², David Hagerty³, Chris Storgard⁴, Robert Mischler⁵ and Robert Morlock⁵, ¹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Division of Rheumatology/Dept. of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, ³Medical, Ardea Bioscience, San Diego, CA, ⁴4939 Directors Place, Ardea Bioscience, San Diego, CA, ⁵Ardea Bioscience, San Diego, CA
Background/Purpose: Gout is a common inflammatory arthritis and its worldwide prevalence is increasing. The purpose of this study is to describe physician, patient and treatment…
Abstract Number: 1901 • 2012 ACR/ARHP Annual Meeting
Chronic Gout. Improvement According to Outcome Meaures in Rheumatology Domains in Daily Clinical Practice
Janitzia Vazquez-Mellado¹, Betsabé Serrano¹, Jaime Mendoza², Sergio Garcia-Mendez¹, V.Chantal Hernández¹, Virginia Pascual Ramos³, Ruben Burgos-Vargas¹ and Marina Rull-Gabayet², ¹Rheumatology, Hospital General de Mexico, Mexico city, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Dept de Immunología y Reumato, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: OMERACT has proposed domains to evaluate the effect of treatment in patients with acute and chronic gout. Their frequency, time to improve and percentage…
Abstract Number: 815 • 2012 ACR/ARHP Annual Meeting
Exploratory Analysis of Radiographic Change in Patients Treated with Intensive Urate-Lowering Therapy
Nicola Dalbeth¹, Anthony Doyle², Fiona M. McQueen³, John S. Sundy⁴ and Herbert S. B. Baraf⁵, ¹Medicine, University of Auckland, Auckland, New Zealand, ²University of Auckland, Auckland, New Zealand, ³Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand, ⁴Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, ⁵Arthritis & Rheumatism Associates, Wheaton, MD
Background/Purpose: In patients with gout, tophi are strongly associated with radiographic damage. Effective urate-lowering therapy (ULT) reduces tophus size. However, no studies to date have…
Abstract Number: 143 • 2012 ACR/ARHP Annual Meeting
Proposed Gout Treatment Guidelines and Meeting Serum Urate and Flare Goals
Jasvinder A. Singh¹, David Hagerty², Chris Storgard³, Robert Mischler⁴ and Robert Morlock⁴, ¹Department of Medicine, University of Alabama, Tuscaloosa, AL, ²Medical, Ardea Bioscience, San Diego, CA, ³4939 Directors Place, Ardea Bioscience, San Diego, CA, ⁴Ardea Bioscience, San Diego, CA
Background/Purpose: Although gout is a relatively common condition, treatment is often not ideal with many patients continuing to experience multiple flares and some developing complications…
Abstract Number: 1903 • 2012 ACR/ARHP Annual Meeting
Oxidation of Urate to Allantoin by Myeloperoxidase in Gout
Lisa K. Stamp¹, Irada Khalilova², Mei Zhang¹, Rufus Turner² and Anthony Kettle², ¹Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²Pathology, University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose : Hyperuricaemia is critical for the development of gout and may play a pivotal role in the pathophysiology of hypertension, metabolic syndrome, and cardiovascular…
Abstract Number: 816 • 2012 ACR/ARHP Annual Meeting
Glomerular Filtration Rate, Chronic Kidney Disease and Incidence of Physician Diagnosed Gout
Eswar Krishnan, Medicine, Standford University, Palo Alto, CA
Background/Purpose: The kidney is the major organ of urate excretion in humans. Yet, there are few studies that assess whether reduced glomerular filtration and/or kidney…
Abstract Number: 144 • 2012 ACR/ARHP Annual Meeting
Long-Term Safety of Canakinumab in Patients with Gouty Arthritis
Alexander So¹, Reike Alten², H. Ralph Schumacher³, Mark Bloch⁴, Thomas Bardin⁵, Markus R. John⁶, Gerhard Krammer⁶, Jan Michael Nebesky⁶, Aiyang Tao⁷ and Naomi Schlesinger⁸, ¹Rheumatology, CHUV, Univ of Lausanne, Lausanne, Switzerland, ²Charité Univ Medicine, Berlin, Germany, ³Department of Medicine, University of Pennsylvania and VA Medical Center, Philadelphia, PA, ⁴Holdsworth House Medical Practice, Sydney, Australia, ⁵Rheumatology, Hôpital Lariboisière, Paris, France, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Gouty arthritis (GA) is a chronic inflammatory disease. Targeting the inflammatory pathway through IL-1β inhibition with canakinumab (CAN) may provide significant long-term benefits. CAN…
Abstract Number: 1904 • 2012 ACR/ARHP Annual Meeting
Patterns of Gout Treatment and Related Outcomes in US Community Rheumatology Practices: the Relation Between Gout Flares, Time in Treatment, Serum Uric Acid Level and Urate Lowering Therapy
Max I. Hamburger¹, John RP Tesser², John L. Skosey³, Allan H. Morton⁴ and Karl M. Kilgore⁵, ¹Rheumatology Associates, Melville, NY, ²AZ Arthritis Rheum Assoc, Paradise Valley, AZ, ³Illinois Bone & Joint Institut, Chicago, IL, ⁴Warren, MI, ⁵Cetus Group, LLC, Hunt Valley, MD
Background/Purpose: Study patterns of gout treatment and related outcomes in US community rheumatology practices, specifically the relation between likelihood and severity of gout flares, time…
Abstract Number: 817 • 2012 ACR/ARHP Annual Meeting
Feasibility of Using a Pharnacist-Based Gout Management Clinic to Improve Serum Uric Acid in Gout Patients an a Large Prepaid Health Plan
Robert D. Goldfien¹, Michele S. Ng², Goldie M. Yip², Alice Hwe², Alice Pressman³ and Andy L. Avins³, ¹Kaiser Permanente, Richmond, CA, ²Pharmacy, Kaiser Permanente, Oakland, CA, ³Division of Research, Kaiser Permanente, Oakland, CA
Background/Purpose: Effective treatment for recurrent gout has been hampered by a number of problems including outdated treatment approaches, a failure to treat to target, and…
Abstract Number: 145 • 2012 ACR/ARHP Annual Meeting
Prevalence of Non-Gout Arthritis in Patients with Gout: Not As Sparing As Previously Thought
Fernando Perez-Ruiz¹ and Ana M. Herrero-Beites², ¹Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain, ²Physical Medicine Division, Hospital de Gorliz, Gorliz, Spain
Background/Purpose: the presence of other chronic inflammatory disease has been historically and academically thought to be “protective” conditions for the development of gout. Objective: to…
Abstract Number: 1906 • 2012 ACR/ARHP Annual Meeting
Changes in Gout patient´s Clinical Profile in the Last Two Decades
Fernando Perez-Ruiz¹ and Ana M. Herrero-Beites², ¹Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain, ²Physical Medicine Division, Hospital de Gorliz, Gorliz, Spain
Background/Purpose: to assess whether changes in the clinical profile of gout are observed in a large cohort of gout patients over the last 20 years.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.